What Does an Imperial Hegemon Mean for Research Ethics?
By Jonathan D. Moreno,
Hastings Center Bioethics Forum
| 02. 09. 2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica. For pretty much everyone else this claim was interesting when identified but paled in comparison to an ongoing global pandemic. During my first few presentations early in 2024 in places like Krakow, Singapore, and Vienna, audiences of academics acknowledged that this was a thing but maybe not an immediate thing.
It turned out to be a pretty immediate thing.
I think it’s fair to say that neither the experts nor the more casual observers (nor this writer), appreciated the Formula One-level acceleration that the still-young year 2026 has already witnessed. If Canadian Prime Minister Mark Carney’s remarks at the World Economic Forum weren’t quite at the historic scale of Winston Churchill’s “iron curtain” speech, they at least set down a marker that the Trump administration had turned U.S. foreign policy in the direction of an “imperial hegemon,” political science jargon...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jenni Fink, Newsweek | 08.19.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump's latest effort to limit birthright citizenship could have consequences for the international surrogacy industry, potentially affecting thousands of intended parents from overseas who travel...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...